Clinical Trial

AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 4, 2025 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
By harnessing artificial intelligence to decode the 12-lead electrocardiogram, the project will enable precise ECG-based phenotyping of hypertrophic cardiomyopathy-accurately classifying septal, apical, and other morphologic subtypes-while simultaneously differentiating HCM from hypertensive heart disease, aortic stenosis, and other phenocopy disorders.
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT07263204
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Hypertrophic Cardiomyopathy (HCM), Left Ventricular Hypertrophy
Enrollment 15,000 participants
Start Date 2025-01-01
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-04